| MRNAModerna | US$149.71 | 12.1% | 331.9% | US$60.0b | US$166.21 | P/S71.1x | -6.1% | n/a |
| PFEPfizer | US$37.16 | 3.1% | 2.0% | US$206.2b | US$40.49 | P/E29.6x | 17.8% | 4.2% |
| TMOThermo Fisher Scientific | US$484.85 | 3.4% | 48.6% | US$187.1b | US$555.98 | P/E30.1x | 0.6% | 0.2% |
| ABBVAbbVie | US$108.22 | 2.7% | 31.8% | US$191.0b | US$121.26 | P/E39.6x | 11.1% | 4.8% |
| ZTSZoetis | US$163.47 | 4.9% | 27.9% | US$77.2b | US$184.29 | P/E47.5x | 12.2% | 0.6% |
| BMYBristol-Myers Squibb | US$63.58 | 2.6% | 5.9% | US$140.0b | US$75.18 | P/S3.4x | 36.4% | 3.1% |
| BNTXBioNTech | US$129.64 | 10.7% | 211.4% | US$31.3b | US$118.16 | P/E1683.4x | 0.9% | n/a |
| ZLABZai Lab | US$161.29 | 26.3% | 170.6% | US$11.7b | US$188.64 | P/S255.9x | 51.6% | n/a |
| MRKMerck | US$76.43 | 0.8% | -7.7% | US$192.9b | US$96.24 | P/E27.4x | 15.1% | 3.4% |
| NVAXNovavax | US$194.66 | 8.9% | 981.4% | US$14.3b | US$323.00 | P/S23.6x | 34.6% | n/a |
| AVTRAvantor | US$32.97 | 5.7% | 131.0% | US$19.1b | US$34.53 | P/E365.4x | 41.6% | n/a |
| MRVIMaravai LifeSciences Holdings | US$37.51 | 14.3% | n/a | US$9.0b | US$48.78 | P/E5x | 19.2% | n/a |
| BIOBio-Rad Laboratories | US$614.85 | 4.6% | 51.6% | US$18.0b | US$658.75 | P/E4.8x | -44.7% | n/a |
| TECHBio-Techne | US$419.45 | 5.1% | 110.5% | US$15.6b | US$397.00 | P/E92.2x | 17.1% | 0.3% |
| IQVIQVIA Holdings | US$207.49 | 1.9% | 64.0% | US$39.9b | US$217.85 | P/E142.3x | 28.4% | 0% |
| TWSTTwist Bioscience | US$140.81 | 9.5% | 415.0% | US$6.8b | US$146.00 | P/S59.1x | -3.7% | n/a |
| AAgilent Technologies | US$132.97 | 1.5% | 68.7% | US$40.0b | US$137.12 | P/E50.6x | 13.1% | 0.6% |
| CVACCureVac | US$95.65 | 3.4% | n/a | US$20.5b | US$84.93 | P/S24.9x | 79.7% | n/a |
| AMGNAmgen | US$249.95 | 0.3% | 10.2% | US$143.3b | US$253.69 | P/E20.2x | 9.0% | 2.8% |
| MTDMettler-Toledo International | US$1,230.86 | 1.7% | 72.9% | US$28.4b | US$1,116.17 | P/E48.8x | 9.0% | n/a |
| QGENQIAGEN | US$52.03 | 4.1% | 29.4% | US$11.8b | US$58.33 | P/E33.1x | 9.3% | n/a |
| BHVNBiohaven Pharmaceutical Holding | US$72.78 | 10.6% | 104.5% | US$4.6b | US$101.91 | P/S67.2x | 62.7% | n/a |
| RGENRepligen | US$212.86 | 3.8% | 102.9% | US$11.7b | US$237.13 | P/E186.7x | 22.4% | n/a |
| CRLCharles River Laboratories International | US$309.82 | 2.5% | 117.3% | US$15.3b | US$319.87 | P/E42.1x | 11.8% | n/a |
